User Fee “Reverse Trigger” Added To House FDA Reform Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Additional fees for postmarketing activity would not be assessed if funds were appropriated from general revenue.
You may also be interested in...
Limits On Pediatric Exclusivity And DTC Advertising Stripped From FDA Bill During Subcommittee Markup
Full Committee Chairman Dingell joins many Democrats in voting to establish civil fines and a pre-submission requirement for TV ads instead of the potential three-year moratorium set out in the draft bill.
BIO Helps Launch Coalition To Increase FDA Funding, Reduce User Fees Reliance
The Coalition for a Stronger FDA will lobby the administration before shifting its focus to congressional appropriators.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.